drugset / Trial / NCT00040105
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
Phase 1
Completed
26 enrolled
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest safe dose of the drugs ZarnestraTM (R115777) and Gleevec (imatinib mesylate) that can be given in combination for the treatment of chronic myelogenous leukemia (CML) in chronic phase. The effect of this combination on the leukemia will also be studied.
Timeline
- Start
- 2002-10
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 300 mg | Oral |
| Subject | tipifarnib | Small molecule | 300 mg | Oral |